BAX and Cirrhosis: On the other hand, there was significant increase (P<0.001) in the level of Bax in silymarin-treated Group 3, low dose CLRE-treated Group 4 and high dose CLRE-treated group 5 (4.98 ± 0.11, 4.47 ± 0.15 and 5.43 ± 0.12 ng/mL respectively) compared to the cirrhosis group 2.